Ameya Prabhakar
Ameya Prabhakar has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ekta Singh
University of Texas Medical Branch at Galveston
1 shared publication - Eshant Bhatia
Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, USA
1 shared publication - Nadim Ahamad
Nanomedicine Lab, Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India
1 shared publication - Rinti Banerjee
Department of Biosciences and Bioengineering, Indian Institute of Technology, Bombay, Powai, Mumbai, India
1 shared publication - Shivam Sharma
University of Toronto
1 shared publication - Sourabh Mehta
Canary Center for Cancer Early Detection, Department of Radiology, Stanford University School of Medicine, Palo Alto, CA 94304, USA
1 shared publication
Latest Publications
- 18 May 2020
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 12 (24) , 12673-12697
Trigger-responsive engineered-nanocarriers and image-guided theranostics for rheumatoid arthritis
Rheumatoid Arthritis (RA), one of the leading causes of disability due to progressive autoimmune destruction of synovial joints, affects ∼1% of the global population. Standard therapy helps in reducing inflammation and delaying the progression of RA but is limited by non-responsiveness on long-term use and several side-effects. The conventional nanocarriers (CNCs), to some extent, minimize toxicity associated with free drug administration while improving the therapeutic efficacy. However, the uncontrolled release of the encapsulated drug even at off-targeted organs limits the application of CNCs. To overcome these challenges, trigger-responsive engineered nanocarriers (ENCs) have been recently explored for RA treatment. Unlike CNCs, ENCs enable precise control over on-demand drug release due to endogenous triggers in arthritic paws like pH, enzyme level, oxidative stress, or exogenously applied triggers like near-infrared light, magnetic field, ultrasonic waves, etc. As the trigger is selectively applied to the inflamed joint, it potentially reduces toxicity at off-target locations. Moreover, ENCs have been strategically coupled with imaging probe(s) for simultaneous monitoring of ENCs inside the body and facilitate an ‘image-guided-co-trigger’ for site-specific action in arthritic paws. In this review, the progress made in recently emerging ‘trigger-responsive’ and ‘image-guided theranostics’ ENCs for RA treatment has been explored with emphasis on the design strategies, mechanism, current status, challenges, and translational perspectives.
- 18 May 2020
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 12 (24) , 12673-12697
Trigger-responsive engineered-nanocarriers and image-guided theranostics for rheumatoid arthritis
Rheumatoid Arthritis (RA), one of the leading causes of disability due to progressive autoimmune destruction of synovial joints, affects ∼1% of the global population. Standard therapy helps in reducing inflammation and delaying the progression of RA but is limited by non-responsiveness on long-term use and several side-effects. The conventional nanocarriers (CNCs), to some extent, minimize toxicity associated with free drug administration while improving the therapeutic efficacy. However, the uncontrolled release of the encapsulated drug even at off-targeted organs limits the application of CNCs. To overcome these challenges, trigger-responsive engineered nanocarriers (ENCs) have been recently explored for RA treatment. Unlike CNCs, ENCs enable precise control over on-demand drug release due to endogenous triggers in arthritic paws like pH, enzyme level, oxidative stress, or exogenously applied triggers like near-infrared light, magnetic field, ultrasonic waves, etc. As the trigger is selectively applied to the inflamed joint, it potentially reduces toxicity at off-target locations. Moreover, ENCs have been strategically coupled with imaging probe(s) for simultaneous monitoring of ENCs inside the body and facilitate an ‘image-guided-co-trigger’ for site-specific action in arthritic paws. In this review, the progress made in recently emerging ‘trigger-responsive’ and ‘image-guided theranostics’ ENCs for RA treatment has been explored with emphasis on the design strategies, mechanism, current status, challenges, and translational perspectives.